CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease-Reference-Cited by-同舟云学术

CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease

Published:2003-04 Issue:1 Volume:121 Page:36-43
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Guikema Jeroen E. J.,Hovenga Sjoerd,Vellenga Edo,Conradie Jelle J.,Abdulahad Wayel H.,Bekkema Roelof,Smit Jan W.,Zhan Fenghuang,Shaughnessy John,Bos Nicolaas A.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.2003.04260.x/fullpdf

Reference40 articles.

1. Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction;Agematsu;Blood,1998

2. Plasma cell generation from B-lymphocytes via CD27/CD70 interaction;Agematsu;Leukemia and Lymphoma,1999

3. CD27: a memory B-cell marker;Agematsu;Immunology Today,2000

4. The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family;Camerini;Journal of Immunology,1991

5. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival;Durie;Cancer,1975

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines;Cytometry Part B: Clinical Cytometry;2024-08-21

2. Prognostic marker CD27 and its micro-environmental in multiple myeloma;BMC Cancer;2024-03-19

3. Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM);Annals of Hematology;2023-12-05

4. Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice;Clinical Lymphoma Myeloma and Leukemia;2023-11

5. Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome;Heliyon;2023-09